StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
November 29, 2021 6:45 AM
Shares of Merck (NYSE: MRK) are down 1.7% in pre-open Monday after Citi analyst Andrew Baum downgraded to Neutral from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Hot Comments
Hot Downgrades
Next Articles
AbbVie (ABBV) Submits Application for Risankizumab to the EMA
November 30, 2021 8:06 AM
Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
November 30, 2021 6:45 AM
AstraZeneca's (AZN) Lynparza Granted Priority Review by the FDA
November 30, 2021 5:34 AM
Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021 5:52 AM
Merck (MRK) PT Lowered to $82 at Morgan Stanley
November 29, 2021 1:56 AM
FDA posts briefing documents on Merck (MRK) /Ridgeback antiviral molnupiravir
November 26, 2021 9:07 AM
